NCT05018416Phase 2Completed

Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)

Study sponsor: Prokidney

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2025-05-20Actual

Enrollment · participants53Actual

Source updated2026-03-13Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Chronic Kidney Diseases; Type 1 Diabetes Mellitus; Type 2 Diabetes Mellitus

Treatments or interventions studied

Renal Autologous Cell Therapy (REACT)BiologicalAlso known as rilparencel

Primary outcomes · main study measures

Read the study measures

measure: Improvement in renal function progression rate as indicated by the change from pre-injection baseline value in total (acute + chronic) slope of estimated glomerular filtration rate (eGFR) using the CKD-EPI 2009 equation; timeFrame: Screening thru month 28; measure: Procedural and investigational product-related treatment-emergent adverse events (TEAEs) obtained through 18 months after the last REACT injection.; timeFrame: Screening thru 18 months after the last injection of study drug

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history